We are analyzing https://link.springer.com/article/10.1007/s10545-013-9608-0.

Title:
Blood–brain barrier structure and function and the challenges for CNS drug delivery | Journal of Inherited Metabolic Disease
Description:
The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood–brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the ‘neurovascular unit’ (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, article, pubmed, cas, barrier, bloodbrain, brain, drug, disease, vitro, mol, cells, model, cell, cns, storage, endothelial, permeability, lysosomal, transport, models, mouse, metab, pharm, abbott, nervous, system, therapy, res, delivery, enzyme, human, central, nat, sci, neurovascular, diseases, function, pericytes, replacement, mucopolysaccharidosis, bbb, transporters, transcytosis, curr, biol, unit, blood, resistance,

Topics {✒️}

month download article/chapter wnt/beta-catenin signaling hcmec/d3 cell line advanced glycation end-products blood–brain barrier integrity including genetically-modified animals human blood–brain barrier blood–brain barrier permeation blood–brain barrier cells blood–brain barrier impairment blood–brain barrier disruption enzyme replacement therapy blood–brain barrier studies blood–brain barrier structure platelet-derived growth factor carrier-mediated transport systems blood–brain barrier transport structure-activity relationship study related subjects blood–brain barrier model brain-cerebrospinal fluid barrier poly-specific drug binding blood-cerebrospinal fluid barriers blood–brain barrier penetration long-term aspirin treatment brain barrier biology inherited metabolic disease predict drug permeation central nervous system p-glycoprotein deficient mouse full article pdf low passive permeability mannose-6-phosphate receptor print] pubmed pmid brain endothelial cells brain gene therapy blood–brain barrier blood brain barrier blood-brain barrier blood–brain barriers endothelial cells lining cerebromicrovascular endothelial cells gene therapy augments hcmec/d3 cells privacy choices/manage cookies improved low-permeability increased capillary permeability examining bbb permeation peptide-modified aavs langford-smith kj

Questions {❓}

Avdeef A (2011) How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability?
Costantino L, Boraschi D (2012) Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?
Martin I (2004) Prediction of blood–brain barrier penetration: are we missing the point?
Stanimirovic DB, Friedman A (2012) Pathophysiology of the neurovascular unit: disease cause or consequence?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Blood–brain barrier structure and function and the challenges for CNS drug delivery
         description:The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood–brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the ‘neurovascular unit’ (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.
         datePublished:2013-04-23T00:00:00Z
         dateModified:2013-04-23T00:00:00Z
         pageStart:437
         pageEnd:449
         sameAs:https://doi.org/10.1007/s10545-013-9608-0
         keywords:
            Enzyme Replacement Therapy
            Gauche Disease
            Miglustat
            Brain Endothelium
            Parallel Artificial Membrane Permeability Assay
            Metabolic Diseases
            Human Genetics
            Pediatrics
            Internal Medicine
            Biochemistry
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig3_HTML.gif
         isPartOf:
            name:Journal of Inherited Metabolic Disease
            issn:
               1573-2665
               0141-8955
            volumeNumber:36
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:N. Joan Abbott
               affiliation:
                     name:King’s College London
                     address:
                        name:BBB Group, Institute of Pharmaceutical Science, King’s College London, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Blood–brain barrier structure and function and the challenges for CNS drug delivery
      description:The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood–brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the ‘neurovascular unit’ (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.
      datePublished:2013-04-23T00:00:00Z
      dateModified:2013-04-23T00:00:00Z
      pageStart:437
      pageEnd:449
      sameAs:https://doi.org/10.1007/s10545-013-9608-0
      keywords:
         Enzyme Replacement Therapy
         Gauche Disease
         Miglustat
         Brain Endothelium
         Parallel Artificial Membrane Permeability Assay
         Metabolic Diseases
         Human Genetics
         Pediatrics
         Internal Medicine
         Biochemistry
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10545-013-9608-0/MediaObjects/10545_2013_9608_Fig3_HTML.gif
      isPartOf:
         name:Journal of Inherited Metabolic Disease
         issn:
            1573-2665
            0141-8955
         volumeNumber:36
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:N. Joan Abbott
            affiliation:
                  name:King’s College London
                  address:
                     name:BBB Group, Institute of Pharmaceutical Science, King’s College London, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Inherited Metabolic Disease
      issn:
         1573-2665
         0141-8955
      volumeNumber:36
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:King’s College London
      address:
         name:BBB Group, Institute of Pharmaceutical Science, King’s College London, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:N. Joan Abbott
      affiliation:
            name:King’s College London
            address:
               name:BBB Group, Institute of Pharmaceutical Science, King’s College London, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:BBB Group, Institute of Pharmaceutical Science, King’s College London, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(385)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.04s.

LINK . SPRINGER . COM {}